PE-22-28: a channel target, not an established antidepressant
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

PE-22-28 comes from research on shortened versions of spadin. Its story begins with an ion channel called TREK-one. Scientists tested how these peptides affected channel activity, stability and behaviour in mice. Those experiments explored a possible route for antidepressant drug development. A change in a mouse behavioural test is not proof that a person’s depression will improve. It also cannot establish human brain exposure, long-term safety or comparative effectiveness. Use the phrase experimental candidate, and keep the evidence level visible. The research provides a hypothesis to test, not a replacement for established mental-health care.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
https://pmc.ncbi.nlm.nih.gov/articles/PMC5601071/
Primary channel assays and mouse behavioral research

[2] Spadin, a sortilin-derived peptide targeting rodent TREK-1 channels
https://pubmed.ncbi.nlm.nih.gov/20405001/
Primary mouse and cellular research on parent spadin

EVIDENCE LIMITATIONS
Do not call mouse behavioral findings a rapid antidepressant effect in humans.
Do not extrapolate parent spadin results to every PE-22-28 derivative.
No suggested substitution for prescribed mental-health treatment.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1093645270203895/